



British Pharmacopoeia

British Pharmacopoeia Commission Secretariat
MHRA, 10 South Colonnade
Canary Wharf, London
E14 4PU, United Kingdom
pharmacopoeia.com

Date: 28 May 2024

TO WHOM IT MAY CONCERN

OXYTETRACYCLINE TABLETS BP 2025

RELATED SUBSTANCES LIMITS

It has come to our attention that the impurity A limit in the Related Substances test for Oxytetracycline Tablets in the BP2025 is incorrect. The monograph currently states a limit of 0.5% for impurity A, however this should be 0.7%.

The limit will be amended as follows:

“the area of any peak corresponding to impurity A is not greater than seven times the area of the principal peak in the chromatogram obtained with solution (5) (0.7%);”

Please accept this as a notice of intent to amend the monograph on behalf of the British Pharmacopoeia Commission. This letter is for information only and does not represent a legally-enforceable standard. The revised monograph will be published in a future edition of the British Pharmacopoeia - the current target publication is the BP 2026, which will come into force on 1st January 2026.

If you have any questions concerning this letter, please do not hesitate to contact the British Pharmacopoeia Secretariat (BPCOM@mhra.gov.uk)

Yours faithfully,

MR STEVE HOARE

Secretary & Scientific Director

Email: BPCOM@mhra.gov.uk